DKK586.1m market cap
DKK3.35 last close
BioPorto is a diagnostic company focused on the development and marketing antibodies and other products for research and diagnostics. This includes products marketed for research use and The NGAL Test for the prediction of kidney failure.
Investment summary
BioPorto announced the decision to supplement its 510(k) paediatric application with additional data, rather than withdraw it. The FDA’s decision relating to The NGAL Test’s use in the risk assessment of acute kidney injury (AKI) in paediatric populations is expected by year end. In addition, the adult AKI programme is on track with expected FDA submission by year end. Our valuation is DKK993m (DKK5.67 per basic share).
Y/E Dec |
Revenue (DKKm) |
EBITDA (DKKm) |
PBT (DKKm) |
EPS (ore) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 25.2 | (33.1) | (34.2) | (20.59) | N/A | N/A |
| 2018A | 26.0 | (42.1) | (42.5) | (24.34) | N/A | N/A |
| 2019E | 31.5 | (60.8) | (62.3) | (32.13) | N/A | N/A |
| 2020E | 53.7 | (54.5) | (54.7) | (26.86) | N/A | N/A |
Industry outlook
The current standard of care for detecting AKI is serum creatinine, which can take 24 hours or more to detect AKI and can only do so after significant kidney damage. NGAL promises to provide a quicker and more reliable test, allowing early intervention to preserve kidney function.
Last updated on 15/11/2019
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (DKKm) | 20.3 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Thomas Magnussen | Chairman |
| Peter Mørch Eriksen | CEO |
| Ole Larsen | CFO |
| Jan Kuhlmann Andersen | COO |
Content on BioPorto Diagnostics
You may also be interested in…
- 4SC
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- ASIT biotech
- Basilea Pharmaceutica
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- MOLOGEN
- Nanobiotix
- NeuroVive Pharmaceutical
- Newron Pharmaceuticals
- Nuevolution
- Oncology Venture
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Photocure
- Pixium Vision
- Probiodrug
- Quantum Genomics
- RhoVac
- Ryvu Therapeutics
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma